Abstract 13093: Predictors for the Favorable Change of Fibrous-cap in Non-culprit Lipid Plaques in Response to Statin Therapy: A Serial Optical Coherence Tomography Study
Introduction: Previous studies demonstrated that statins improved fibrous cap thickness (FCT) in patients with coronary artery disease. However, factors affecting the favorable FCT change in response to statin therapy remain unknown.
Aim: To identify the clinical factors for favorable FCT change of non-culprit coronary plaques with statin therapy in patients with coronary artery disease.
Methods: A total of 152 non-culprit plaques from 90 patients who were treated with statin and had serial optical coherence tomography (OCT) imaging at baseline and follow-up were included. FCT was assessed at the thinnest portion within the entire plaque.
Results: The mean FCT was improved from 105.7 ± 52.3 μm to 128.4 ± 60.7 μm (P<0.001) from baseline to follow-up (median 6.38 [6.07-12.5] months). Multivariate liner regression analysis demonstrated that the percent change of FCT was significantly correlated to the eGFR at baseline (B=1.043, 95% confidential interval (CI) [0.321, 1.765], P=0.005) (Table). The percent change of FCT in patients with CKD Stage 1 (eGFR≥90) was significantly greater (42.3% [6.45, 100.0]) than in those with Stage 2 (eGFR: 60-89) (0.0% [-21.6, 58.5], P=0.007) or with Stage≥3 (eGFR<60) (0.0% [-14.3, 54.5], P=0.033) (Figure).
Conclusions: Higher eGFR value at baseline was significantly correlated to the greater FCT improvement of non-culprit coronary plaques with statin therapy. Patients with eGFR≥90, in particular, had best response to statin therapy.
Author Disclosures: Y. Minami: None. D. Ong: None. S. Uemura: None. Z. Wang: None. A. Aguirre: None. S. Mukhopadhyay: None. T. Soeda: None. R. Vergallo: None. L. Gao: None. L. Xing: None. H. Lee: None. B. Yu: None. I. Jang: Research Grant; Significant; St. Jude Medical, Boston Scientific Corp, Medtronic Inc.
- © 2015 by American Heart Association, Inc.